EastPharma announced audited earnings results for the year ended December 31, 2017. According to IFRS results, revenue in twelve months of 2017 was USD 220.4 million compared to USD 224.9 million in 2016, down 2.0% from the same period in 2016. EBITDA was USD 55.6 million compared to USD 55.8 million in 2016 representing an EBITDA margin of 25.2% compared to 24.8% in 2016. Profit before tax was USD 30.2 million compared to USD 24.3 million a year ago. Net profit for the year was USD 27.8 million compared to USD 18.5 million a year ago. Attributable to equity holders of the parent was USD 23.5 million compared to USD 15.4 million a year ago. Basic and diluted earnings per share USD 0.35 compared to USD 0.23 a year ago. Net cash provided by operating activities was USD 25.3 million compared to USD 54.987 million a year ago. Purchases of property, plant and equipment was USD 22.8 million compared to USD 15.1 million a year ago. Purchases of intangible assets was USD 13.8 million compared to USD 16.0 million a year ago.